Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bms 284756
2. Bms-284756
3. Bms284756
4. Garenoxacin
1. Garenoxacin Mesylate
2. 223652-82-2
3. Bms 284756
4. Bms-284756
5. 437zku48cf
6. Garenoxacin Methanesulfonate
7. Garenoxacin Mesylate Anhydrous
8. Unii-437zku48cf
9. Bms 284756-01
10. Schembl1649428
11. Dtxsid4058732
12. Bcp17552
13. T 3811me
14. Garenoxacin Mesilate [mart.]
15. Garenoxacin Mesilate [who-dd]
16. Garenoxacin Mesylate / Methanesulfonate
17. Garenoxacin Methanesulfonate [mi]
18. (+)-garenoxacin Mesylate Anhydrous
19. 652g902
20. Q27258626
21. (r)-1-cyclo-propyl-8-difluoromethoxy-7-(1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid Methanesulfonate
22. (r)-1-cyclopropyl-8-(difluoromethoxy)-7-(1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid Methanesulfonate
23. (r)-1-cyclopropyl-8-difluoromethoxy-7-(1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid Methanesulfonate
24. 1-cyclopropyl-8-(difluoromethoxy)-7-((1r)-1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid Mesylate
25. 1-cyclopropyl-8-(difluoromethoxy)-7-(1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid Methanesulfonate Monohydrate
26. 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2,3-dihydro-1h-isoindol-5-yl]-4-oxoquinoline-3-carboxylic Acid;methanesulfonic Acid
27. 3-quinolinecarboxylic Acid, 1-cyclopropyl-8-(difluoromethoxy)-7-((1r)-2,3-dihydro-1-methyl-1h-isoindol-5-yl)-1,4-dihydro-4-oxo-, Monomethanesulfonate
28. 3-quinolinecarboxylic Acid, 1-cyclopropyl-8-(difluoromethoxy)-7-((1r)-2,3-dihydro-1-methyl-1h-isoindol-5-yl)-1,4-dihydro-4-oxo-, Methanesulfonate (1:1)
| Molecular Weight | 522.5 g/mol |
|---|---|
| Molecular Formula | C24H24F2N2O7S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 5 |
| Exact Mass | 522.12722861 g/mol |
| Monoisotopic Mass | 522.12722861 g/mol |
| Topological Polar Surface Area | 142 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 863 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A Garenoxacin Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Garenoxacin Mesylate, including repackagers and relabelers. The FDA regulates Garenoxacin Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Garenoxacin Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Garenoxacin Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Garenoxacin Mesylate supplier is an individual or a company that provides Garenoxacin Mesylate active pharmaceutical ingredient (API) or Garenoxacin Mesylate finished formulations upon request. The Garenoxacin Mesylate suppliers may include Garenoxacin Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Garenoxacin Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Garenoxacin Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Garenoxacin Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Garenoxacin Mesylate GMP manufacturer or Garenoxacin Mesylate GMP API supplier for your needs.
A Garenoxacin Mesylate CoA (Certificate of Analysis) is a formal document that attests to Garenoxacin Mesylate's compliance with Garenoxacin Mesylate specifications and serves as a tool for batch-level quality control.
Garenoxacin Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Garenoxacin Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Garenoxacin Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Garenoxacin Mesylate EP), Garenoxacin Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Garenoxacin Mesylate USP).
LOOKING FOR A SUPPLIER?
